DE-LYCRA
27.7.2021 11:02:09 CEST | Business Wire | Press release
The LYCRA Company , a global leader in developing innovative solutions for the textile, apparel, and personal care industries, today introduced a breakthrough LYCRA® FitSense™ technology innovation that reduces or eliminates the need for bra foam. This patent-pending bra cup application can be used in intimate apparel such as traditional wired, non-wired or unlined bras (including bralettes and sport bras), plus activewear and swimwear.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005390/en/
LYCRA® FitSense™ technology is a water-based, solvent-free dispersion that is comprised of the same molecule as LYCRA® fiber. The dispersion is screen-printed directly onto the bra fabric, increasing the power of the fabric in precise areas. The power increase in the bra cup effectively reduces nipple protrusion while providing symmetrical support, shaping and lift for the bustline—reducing or eliminating the need for sewn-in panels or insertable pads.
Zones of support can be applied to the bottom and sides of the bra cup for shaping, as well as the wing for maximum comfort and smoothing. LYCRA® FitSense™ technology also can be applied between fabric layers in the bra cup to mask nipple protrusion while retaining the original fabric aesthetics.
“With LYCRA® FitSense™ technology, the print does the work of the pad and enables brands to build a better bra for all sizes, styles and silhouettes—a true breakthrough development,” said Melissa Stewart, global technology director-R&D materials innovations. “With this new innovation, women have more choices in bras that provide functionality, style and comfort.”
Bras can be rigid, bulky, and hot, with multiple components and structures creating an uncomfortable, restrictive wearing experience. LYCRA® FitSense™ technology can be used to design functional bras that are lighter, thinner, and more breathable, without sacrificing modesty, all-day comfort, durability, support or shaping. And unlike polyurethane foam—which discolors and can move around or even get lost in the wash—LYCRA® FitSense™ technology is built into the garment and is highly durable to machine washing and regular wear. Further, in swimwear applications, the technology provides chlorine resistance and fast drying benefits versus foams and dual fabric layers.
LYCRA® FitSense™ technology offers intimate apparel makers versatility to create intentional design aesthetics by incorporating delicate patterns and artistic details that align with their brand identities. “Designs and colors can be easily customized to deliver on-trend fashion cues—from feminine, lacelike designs to sporty geometric shapes—that satisfy all tastes,” said Stewart. “With LYCRA® FitSense™ technology, a designer’s imagination is the only creative limitation.”
LYCRA® FitSense™ technology, which achieved the ECO PASSPORT by OEKO-TEX® sustainability certification, is applied using standard screen-printing processes, eliminating the need for specialty equipment or major supply chain upgrades. The LYCRA Company provides technical guidance to enable brands, retailers, and garment makers to easily access this innovation.
For more information, download our white paper on the LYCRA FitSense™ technology and screen-printed bra cup application.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA® , LYCRA HyFit® , LYCRA® T400® , COOLMAX® , THERMOLITE® , ELASPAN® , SUPPLEX® , and TACTEL® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA® FitSense™ is a trademark of The LYCRA Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005390/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom